Month: July 2025

Introduction and Objective: Preserving β-cell function may delay or prevent progression to CF-related diabetes, a major comorbidity in people with PI-CF. This study aimed to evaluate whether weekly GLP-1 agonist therapy improves β- and α-cell function and post-prandial glucose tolerance in people with PI-CF and AGT. Methods: In this randomized, open-label, cross-over study, participants received […]

Introduction and Objective: Exercise is key in diabetes management, yet patients’ knowledge and absence of exercise specialists may be limiting factors. Physical therapists (PTs), as exercise specialists, should be part of diabetes care. Yet PTs knowledge of diabetes in the US and abroad is limited. The aim of this study was to 1) compare baseline […]

Introduction and Objective: Type 1 diabetes (T1D) causes significant stress in affected individuals, which may be worse in those from resource-limited countries. We assessed diabetes distress and quality of life (QOL) among Ugandan children and young adults with T1D and their parents.Methods: Patients aged 4-26yr from two paediatric T1D clinics in Kampala participated. Diabetes distress […]

Introduction and Objective: Presymptomatic Stage 2 type 1 diabetes (T1D) is characterized by ≥2 autoantibodies and dysglycemia due to a progressive decline of β-cell function, eventually leading to symptomatic Stage 3 T1D. We aim to develop a risk progression model with the potential to assess the effectiveness of therapeutic interventions to delay T1D onset.Methods: Twenty-three […]

Introduction and Objective: Type 2 Diabetes (T2D) can lead to ischemic conditions in lower limbs and the following risk of diabetic foot ulcer (DFU). Data linking vitamin D and lower extremity arterial plague (LEAP) and its adverse event, i.e. DFU, are limited.Methods: We enrolled 7479 hospitalized patients (2378 men and 3105 women aged 30 to […]

Introduction and Objective: The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in diabetes treatment is expanding. This study evaluated the efficacy and safety of henagliflozin combined with continuous subcutaneous insulin infusion (CSII) in type 2 diabetes (T2DM) based on continuous glucose monitoring system (CGM).Methods: In this multicenter, randomized, open-Label, controlled study, 210 patients who had […]

Introduction and Objective:IntroductionAdvancements in blood glucose measurement and insulin dosing over the past two decades have improved outcomes for individuals with Type 1 diabetes (T1D). However, chronic kidney disease (CKD) remains a significant management challenge. The frequency of specialist outpatient (OP) appointments could serve as a proxy for disease severity. This study aimed to determine […]

Introduction and Objective: Guidelines recommend GLP-1 receptor agonists (GLP-1-RA) and SGLT2 inhibitors (SGLT2i) for individuals with type 2 diabetes (T2D) at high risk of atherosclerotic cardiovascular disease (ASCVD). We aimed to develop a personalized treatment algorithm to guide the initial decision between these therapies.Methods: Using data from the Diabetes Prospective Follow-up registry (Germany/Austria) we studied […]

Introduction and Objective: Continuous glucose monitoring (CGM) is a diagnostic tool widely used to monitor glucose levels in patients with diabetes and to guide insulin dose adjustments in outpatients. In the critical setting of inpatient care, however, special regulatory requirements on glucose measurements necessitate accuracy of CGM measurements as a prerequisite for its integration into […]